K Pharma

K Pharma Current Liabilities

The Current Liabilities of K Pharma (4896.T) as of Oct 17, 2026 is 171.17 M JPY. In the previous year, Current Liabilities was 110.87 M JPY — a change of 54.39% (higher).

Current Liabilities

171.17 MJPY

YoY

54.39%

Last updated:

Current Liabilities of K Pharma is 2025 171.17 M JPY. Current Liabilities of K Pharma was 2024 110.87 M JPY. It decreases by 54.39% higher compared to the previous year.

The K Pharma Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2021
40.62 M JPY
Jan 1, 2022
53.33 M JPY
Jan 1, 2023
139.01 M JPY
Jan 1, 2024
110.87 M JPY
Jan 1, 2025
171.17 M JPY
The K Pharma Current Liabilities history
YEARCurrent LiabilitiesYoY
171.17 MJPY+54.39%
110.87 MJPY-20.24%
139.01 MJPY+160.67%
53.33 MJPY+31.28%
40.62 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

K Pharma Stock analysis

What does K Pharma do? K Pharma Inc is a Japan-based pharmaceutical company headquartered in Minato-ku, Tokyo. The company operates in the Health Care sector, specifically within the Pharmaceuticals industry. It has a small team of 13 full-time employees. K Pharma Inc completed its initial public offering (IPO) on October 17, 2023, with the ticker symbol 4896.T and ISIN JP3280900006. The company's website is https://kpharma.co.jp/. K Pharma Inc focuses on the research, development, manufacture, and sale of pharmaceuticals. It is engaged in the field of induced pluripotent stem cell (iPS) drug discovery, which involves creating neural progenitor cells from iPS cells. These cells are cryopreserved and used in a treatment process where 200,000 cells are transplanted via injection into the spinal cord injury site of patients. The company also conducts research, development, manufacture, and sale of regenerative medicine products. K Pharma Inc operates through a single business segment, concentrating on pharmaceutical and regenerative medicine solutions. The company's activities are centered on developing innovative treatments, particularly in the area of spinal cord injury recovery using stem cell technology. K Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about K Pharma stock

Current Liabilities of K Pharma is 171.17 M JPY in 2025.

Current Liabilities of K Pharma changed from 110.87 M JPY to 171.17 M JPY, representing a 54.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities K Pharma since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's K Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — K Pharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — K Pharma